Parameter | Patients (total) | Patients (progressed) | Time to progression (years) | p-value | ||
---|---|---|---|---|---|---|
TNM status at diagnosis | T0-T1 | 77 | 28 | 5.10 | 4.13- n.e. | 0.1423 |
T2-T4 | 176 | 92 | 4.06 | 3.56-7.74 | ||
N0 | 74 | 37 | 4.11 | 3.30-6.05 | 0.2813 | |
N1-N3 | 165 | 75 | 5.06 | 4.05-9.76 | ||
M0 | 171 | 79 | 5.06 | 4.05-9.70 | 0.2367 | |
M1 | 64 | 31 | 4.39 | 3.51-6.58 | ||
Grading | G1-G2 | 132 | 63 | 4.13 | 3.55-6.05 | 0.3122 |
G3 | 118 | 55 | 5.06 | 4.04-9.53 | ||
Disease-free survival | 0-5 years | 203 | 91 | 5.12 | 4.11-8.72 | 0.2183 |
>5 years | 56 | 32 | 3.46 | 3.00-4.44 | ||
Hormone receptor status | ER negative | 109 | 48 | 5.96 | 4.04-9.53 | 0.1876 |
ER positive | 148 | 73 | 4.13 | 3.55-6.05 | ||
PR negative | 132 | 61 | 5.06 | 4.05-6.58 | 0.6547 | |
PR positive | 120 | 56 | 4.11 | 3.53-9.70 | ||
ER and PR negative | 94 | 42 | 5.06 | 4.04-9.53 | 0.3789 | |
ER or PR positive | 157 | 75 | 4.18 | 3.56-6.58 | ||
Age at trastuzumab start | < 50 years | 70 | 32 | 5.96 | 4.11-9.76 | 0.0744 |
≥50 years | 198 | 94 | 4.20 | 3.56-6.05 | ||
ECOG status at trastuzumab start | 0 | 115 | 54 | 4.61 | 3.91-9.76 | 0.0812 |
1-4 | 116 | 59 | 4.05 | 3.44-5.96 | ||
Site of recurrence at trastuzumab start | locoregional | 0.1156 | ||||
recurrent only | 55 | 22 | 9.70 | 3.63-9.70 | ||
Bone metastases only | 41 | 21 | 4.05 | 3.30-n.e. | ||
Visceral metastases | 139 | 69 | 4.39 | 3.55-6.58 | ||
Initial response to trastuzumab treatment | Complete remission | 48 | 16 | 8.72 | 4.46-9.76 | 0.0571 |
Partial remission | 80 | 46 | 4.03 | 3.50-4.41 | ||
Stable disease | 82 | 37 | 4.66 | 3.56-n.e. | ||
Interruption of trastuzumab treatment | no therapy interruption | 251 | 109 | 5.13 | 4.11-9.53 | 0.0005 |
therapy interruption | 14 | 14 | 3.51 | 2.36-4.44 |